A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity
Latest Information Update: 29 Apr 2025
At a glance
- Drugs AMG 513 (Primary) ; AMG 513 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Amgen
Most Recent Events
- 24 Apr 2025 Status changed from active, no longer recruiting to recruiting.
- 21 Mar 2025 Status changed from suspended to active, no longer recruiting.
- 04 Feb 2025 According to an Amgen media release, trial was placed on clinical hold by the U.S. Food and Drug Administration (FDA). Discussions are underway on a path forward to reopen the study.